| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4438164
Max Phase: Preclinical
Molecular Formula: C29H34Cl2N2O5
Molecular Weight: 488.58
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COc1ccc(OCCCN2CCN(Cc3ccc4oc5cc(OC)ccc5c(=O)c4c3)CC2)cc1.Cl.Cl
Standard InChI: InChI=1S/C29H32N2O5.2ClH/c1-33-22-5-7-23(8-6-22)35-17-3-12-30-13-15-31(16-14-30)20-21-4-11-27-26(18-21)29(32)25-10-9-24(34-2)19-28(25)36-27;;/h4-11,18-19H,3,12-17,20H2,1-2H3;2*1H
Standard InChI Key: DZZCYXSYTSWCGI-UHFFFAOYSA-N
Associated Targets(non-human)
Serotonin 2 (5-HT2) receptor 2078 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 488.58 | Molecular Weight (Monoisotopic): 488.2311 | AlogP: 4.55 | #Rotatable Bonds: 9 |
| Polar Surface Area: 64.38 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 6.96 | CX LogP: 4.14 | CX LogD: 4.00 |
| Aromatic Rings: 4 | Heavy Atoms: 36 | QED Weighted: 0.25 | Np Likeness Score: -0.62 |
References
| 1. Żelaszczyk D, Jakubczyk M, Pytka K, Rapacz A, Walczak M, Janiszewska P, Pańczyk K, Żmudzki P, Słoczyńska K, Marona H, Waszkielewicz AM.. (2019) Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system., 29 (21): [PMID:31537425] [10.1016/j.bmcl.2019.126679] |
Source
Source(1):